PRL and pituitary gland adenoma: Bromocriptine is commonly chosen as a therapeutic agent for patients with prolactinomas or other pituitary adenomas; bromocriptine binds to the dopamine D2 receptor on pituitary epithelial cells to inhibit prolactin secretion [2].